UPDATE: Deutsche Bank Reiterates on Amgen Following Biosimilar Conference
In a report published Wednesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Amgen (NASDAQ: AMGN), and raised the price target from $138.00 to $142.00.
In the report, Deutsche Bank noted, “We attended a biosimilar conference in order to learn more about the OPP'Y for Amgen. We came away with a greater understanding as to the impact of Biosimilars on AMGN's base biz & have adjusted our model accordingly. We also grew more comfortable in the Biosmilar opp'y for AMGN. We now include a probability adjusted Biosimilar revs beyond 2017 & note net/net biosimilars have a positive NPV to AMGN. Please ask for our Biosimilar APP.”
Amgen closed on Tuesday at $115.46.
Latest Ratings for AMGN
|Feb 2016||Argus Research||Maintains||Buy|
|Feb 2016||Leerink Swann||Initiates Coverage on||Market Perform|
|Jan 2016||Credit Suisse||Maintains||Outperform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.